HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy.

J Transl Med · 2012 · PMC3275536 · PMID 22240029

Europe PMC DOI

hedged sentences

0.0660

closest p · 1.3× alpha

0.0660

boldest claim

The sentences

did not reach statistical significancep = 0.066so close (0.05 < p ≤ 0.1)

In addition, although HER2 3+ tumors were more often of high grade, this feature did not reach statistical significance (p = 0.066), but significantly more high-grade tumors were positive for TopoIIa protein (p < 0.001).

also in 111,027 other papers

showed a trendno p-value reported

Finally, patients with tumors carrying HER2/TOP2A co-amplification showed a trend for favorable disease-free survival in comparison to tumors where only one or none of the two genes was amplified.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.